These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7792038)

  • 41. [Loss of bone substance in long-term dialysis--the value of serochemical parameters].
    Schober HC; Abendroth K; Osten B; Kunkel S
    Z Urol Nephrol; 1989 Oct; 82(10):515-9. PubMed ID: 2609801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation.
    Goffin E; Devogelaer JP; Lalaoui A; Depresseux G; De Naeyer P; Squifflet JP; Pirson Y; van Ypersele de Strihou C
    Transpl Int; 2002 Mar; 15(2-3):73-80. PubMed ID: 11935163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
    Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
    Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Study on vascular calcification in patients on continuous ambulatory peritoneal dialysis (CAPD): special reference to active vitamin D (VD) treatment].
    Yokoyama K
    Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1171-80. PubMed ID: 8264107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal osteodystrophy in children on CAPD: a prospective trial of 1-alpha-hydroxycholecalciferol therapy.
    Watson AR; Kooh SW; Tam CS; Reilly BJ; Balfe JW; Vieth R
    Child Nephrol Urol; 1988-1989; 9(4):220-7. PubMed ID: 3255485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term treatment of uraemic osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1976; 12():221-6. PubMed ID: 935114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone mineral and calcium metabolism before, during and after treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Eriksson S
    Scand J Rheumatol; 1982; 11(1):55-7. PubMed ID: 7063813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Regression of extraosseous calcinosis in chronic ambulatory peritoneal dialysis treatment].
    Haag B
    Z Urol Nephrol; 1989 Feb; 82(2):81-4. PubMed ID: 2728634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [5 years of continuous ambulatory peritoneal dialysis in the child].
    Nemeth J; Leumann EP
    Klin Padiatr; 1986; 198(1):8-12. PubMed ID: 3959493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of 1-alpha OH D3 therapy in uremic patients in conservative or dialytic treatment.
    Lamperi S; Vagge R
    Int J Artif Organs; 1979 Sep; 2(5):243-7. PubMed ID: 478681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients.
    Goldstein DA; Malluche HH; Massry SG
    Contrib Nephrol; 1980; 18():42-54. PubMed ID: 7353379
    [No Abstract]   [Full Text] [Related]  

  • 52. Longitudinal study of bone mass in end-stage renal disease patients: effects of parathyroidectomy for renal osteodystrophy.
    Copley JB; Hui SL; Leapman S; Slemenda CW; Johnston CC
    J Bone Miner Res; 1993 Apr; 8(4):415-22. PubMed ID: 8475791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of age, sex and body weight on renal osteodystrophy in predialysis patients with chronic renal failure.
    Kumchev EP; Tzvetkova SB; Enchev ED; Yaneva MP; Dimitrova RH; Botushanova AD; Dimitrakov DJ
    Folia Med (Plovdiv); 2000; 42(2):28-33. PubMed ID: 11217280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical analysis of bone diseases in patients under chronic hemopurification].
    Zhu LY
    Zhonghua Yi Xue Za Zhi; 1989 Mar; 69(3):128-30, 10. PubMed ID: 2776053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of sex hormone changes on bone mineral deficit in chronic renal failure.
    Doumouchtsis KK; Perrea DN; Doumouchtsis SK
    Endocr Res; 2009; 34(3):90-9. PubMed ID: 19701834
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of radial bone mineral content with total body calcium in chronic renal failure.
    Cohn SH; Ellis KJ; Caselnova RC; Asad SN; Letteri JM
    J Lab Clin Med; 1975 Dec; 86(6):910-9. PubMed ID: 1194756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone mineral loss in patients on maintenance hemodialysis with hyperphosphatemia treated with 1 alpha-hydroxycholecalciferol and calcium carbonate.
    Nishitani H; Yamakawa M; Nishizawa Y; Morii H
    J Nutr Sci Vitaminol (Tokyo); 1991 Dec; 37 Suppl():S113-8. PubMed ID: 1820437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longitudinal changes in hemostatic factors in CAPD patients.
    Lee MS; Yang WS; Lee SK; Park JS; Chi HS; Kim SB
    Perit Dial Int; 2002; 22(4):518-20. PubMed ID: 12322826
    [No Abstract]   [Full Text] [Related]  

  • 59. Bone disorder following partial and total gastrectomy with reference to bone mineral content.
    Nishimura O; Furumoto T; Nosaka K; Kouno K; Sumikawa M; Hisaki T; Odachi T; Mizumoto K; Kishimoto H; Yamamoto K
    Jpn J Surg; 1986 Mar; 16(2):98-105. PubMed ID: 3723890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 1alpha-hydroxycholecalciferol. Long-term treatment of patients with uraemic osteodystrophy.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Nephron; 1976; 16(5):359-70. PubMed ID: 1264309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.